Get started
Author

Patrick Youngwhan Chun

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
2018 · Stergios J. Moschos, Ryan J. Sullivan, et al. · JCI Insight · 147
PDF
Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma
2006 · Patrick Y. Chun, Felix Y. Feng, et al. · Cancer Research · 79
PDF
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
2019 · Peter Westervelt, Jorge E. Cortes, et al. · Blood · 72
Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity
2006 · F Y Feng, S Varambally, et al. · Oncogene · 72
Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo
2007 · Felix Y. Feng, Carlos A. Lopez, et al. · Clinical Cancer Research · 47
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
2014 · F. Stephen Hodi, Antoni Ribas, et al. · Journal of Clinical Oncology · 40
Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy.
2009 · Patrick Chun, Zev A Wainberg · PubMed · 26
Ataxia Telangiectasia Mutated Down-regulates Phospho-Extracellular Signal-Regulated Kinase 1/2 via Activation of MKP-1 in Response to Radiation
2006 · Mukesh K. Nyati, Felix Y. Feng, et al. · Cancer Research · 26
PDF
Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).
2014 · Omid Hamid, Caroline Robert, et al. · Journal of Clinical Oncology · 25
Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice
2013 · Durga P. Cherukuri, Tomo-o Ishikawa, et al. · Molecular Oncology · 22
PDF
Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
2014 · F Stephen Hodi, Antoni Ribas, et al. · Journal for ImmunoTherapy of Cancer · 12
PDF
Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors.
2021 · Niharika B. Mettu, Alexander Starodub, et al. · Journal of Clinical Oncology · 8
Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer
2010 · Matthew D Schmitz, Gilbert DA Padula, et al. · Radiation Oncology · 6
PDF
A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
2017 · Manish A. Shah, Jean-Philippe Metges, et al. · Journal of Clinical Oncology · 5
Selectivity of T Cell Engager AMV564 Against Different Leukemic Blast Populations and Potential Application for Patient Selection
2020 · Aurelien Sarde, Sterling Eckard, et al. · Blood · 4
Abstract 528: MDSC suppress the T cell repertoire and contribute to a pathologic cytokine milieu in cancer patients
2021 · Sterling Eckard, Aurelien Sarde, et al. · Cancer Research · 3
372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager
2020 · Sarina Piha-Paul, Alexander Starodub, et al. · Regular and Young Investigator Award Abstracts · 3
AMV564 Depletes Myeloid-Derived Suppressor Cells and Expands T Cells: Potential to Address Key Limitations of Cellular Therapies
2021 · Sterling Eckard, Bianca Rojo, et al. · Blood · 2
A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors.
2020 · Alexander Starodub, Sarina Anne Piha-Paul, et al. · Journal of Clinical Oncology · 2
A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
2015 · Mark D. Minden, Wendy Stock, et al. · Blood · 2
849 ReSTORE T cell engager platform depletes MDSC in parallel with antigen-specific solid tumor cytotoxicity
2021 · Sterling Eckard, Bianca Rojo, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
887 Repolarization of T cells by AMV564 in patients progressing on checkpoint blockade
2021 · Victoria Smith, Sterling Eckard, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Data from Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo
2023 · Felix Y. Feng, Carlos A. Lopez, et al.
Data from Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo
2023 · Felix Y. Feng, Carlos A. Lopez, et al.
Supplementary Figure S1 from Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo
2023 · Felix Y. Feng, Carlos A. Lopez, et al.
PDF
Works count: 38
Citation count: 605
H-index: 11
I10-index: 11
Year
Topic
Type